Literature DB >> 12811507

Serum nitric oxide, catalase, superoxide dismutase, and malondialdehyde status in patients with ankylosing spondylitis.

Salih Ozgocmen1, Sadik Sogut, Ozge Ardicoglu, Ersin Fadillioglu, Irfan Pekkutucu, Omer Akyol.   

Abstract

In this study, serum antioxidant and oxygen derived free radical status of patients with ankylosing spondylitis (AS) was investigated and compared with that of age- and sex-matched healthy controls. The relationship of these parameters to disease activity indices was also examined. Thirty patients with AS not currently under disease-modifying antirheumatic drug (DMARD) treatment (e.g., sulfasalazine or methotrexate) (15 active and 15 inactive) and 16 age- and sex-matched healthy controls were included in the study. Catalase (EC 1.11.1.6), total (Cu-Zn and Mn) superoxide dismutase (SOD) (EC 1.15.1.1) activities, and malondialdehyde (MDA), nitrite (NO(2)(-)), and nitrate (NO(3)(-)) levels as indices of nitric oxide (NO) production were evaluated using appropriate methods. There was no statistically significant difference found in SOD activity or NO and MDA levels between active and inactive patients. Inactive patients showed no significant difference in all the measured oxidant/antioxidant parameters when compared to healthy controls. Active patients had significantly higher levels of MDA and catalase enzyme activity ( P=0.002 and P=0.007, respectively). There was no significant correlation between oxidant/antioxidant parameters and disease activity, C-reactive protein, erythrocyte sedimentation rate, or Bath Ankylosing Spondylitis Disease Activity Index (CRP, ESR, or BASDAI) in either group, except catalase enzyme activity, which had a significant correlation with CRP and ESR levels in active patients ( r=0.69 and P=0.004, r=0.52 and P=0.04, respectively). Our results indicate that oxidative stress and lipid peroxidation are accelerated in untreated patients with active AS. Serum catalase activity may be closely related to disease activity. In this regard, we underscore the likely benefit of some therapeutic interventions including high-potential antioxidants that will potentiate the antioxidant defense mechanism and reduce peroxidation in the management of AS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12811507     DOI: 10.1007/s00296-003-0335-y

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  21 in total

1.  [Concentrations of superoxide dismutase (copper and manganese), catalase and glutathione peroxidase in red cells, platelets and plasma in patients with rheumatoid polyarthritis].

Authors:  A Abella; D Clerc; J Chalas; A Baret; R Leluc; A Lindenbaum
Journal:  Ann Biol Clin (Paris)       Date:  1987       Impact factor: 0.459

2.  A simple method for clinical assay of superoxide dismutase.

Authors:  Y Sun; L W Oberley; Y Li
Journal:  Clin Chem       Date:  1988-03       Impact factor: 8.327

3.  Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria.

Authors:  S van der Linden; H A Valkenburg; A Cats
Journal:  Arthritis Rheum       Date:  1984-04

4.  Determination of inorganic nitrate in serum and urine by a kinetic cadmium-reduction method.

Authors:  N K Cortas; N W Wakid
Journal:  Clin Chem       Date:  1990-08       Impact factor: 8.327

5.  Hypoxic-reperfusion injury in the inflamed human joint.

Authors:  D R Blake; P Merry; J Unsworth; B L Kidd; J M Outhwaite; R Ballard; C J Morris; L Gray; J Lunec
Journal:  Lancet       Date:  1989-02-11       Impact factor: 79.321

6.  Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument?

Authors:  A Calin; J P Nakache; A Gueguen; H Zeidler; H Mielants; M Dougados
Journal:  Rheumatology (Oxford)       Date:  1999-09       Impact factor: 7.580

7.  Erythrocyte antioxidant enzymes are reduced in patients with rheumatoid arthritis.

Authors:  A Imadaya; K Terasawa; H Tosa; M Okamoto; K Toriizuka
Journal:  J Rheumatol       Date:  1988-11       Impact factor: 4.666

8.  Nitric oxide release from a single cell measured in situ by a porphyrinic-based microsensor.

Authors:  T Malinski; Z Taha
Journal:  Nature       Date:  1992-08-20       Impact factor: 49.962

9.  Elevated serum nitrate concentrations in active spondyloarthropathies.

Authors:  D O Stichtenoth; J Wollenhaupt; D Andersone; H Zeidler; J C Frölich
Journal:  Br J Rheumatol       Date:  1995-07

10.  Free-radical oxidation (peroxidation) products in serum and synovial fluid in rheumatoid arthritis.

Authors:  J Lunec; S P Halloran; A G White; T L Dormandy
Journal:  J Rheumatol       Date:  1981 Mar-Apr       Impact factor: 4.666

View more
  18 in total

Review 1.  Current concepts in the pathophysiology of fibromyalgia: the potential role of oxidative stress and nitric oxide.

Authors:  Salih Ozgocmen; Huseyin Ozyurt; Sadik Sogut; Omer Akyol
Journal:  Rheumatol Int       Date:  2005-11-20       Impact factor: 2.631

2.  Oxidative stress and related factors in patients with ankylosing spondylitis.

Authors:  Dilek Solmaz; Didem Kozacı; İsmail Sarı; Ali Taylan; Fatoş Önen; Nurullah Akkoç; Servet Akar
Journal:  Eur J Rheumatol       Date:  2016-01-29

Review 3.  Pathophysiology and antioxidant status of patients with fibromyalgia.

Authors:  Riffat Iqbal; M S Mughal; Najma Arshad; Muhammad Arshad
Journal:  Rheumatol Int       Date:  2010-04-08       Impact factor: 2.631

4.  Evaluation of paraoxonase and arylesterase activities in Egyptian patients with ankylosing spondylitis.

Authors:  Shereem Mohamed Olama; Mohammed Mohamed Elarman
Journal:  Rheumatol Int       Date:  2012-12-14       Impact factor: 2.631

5.  Antioxidant status, lipid peroxidation and nitric oxide in fibromyalgia: etiologic and therapeutic concerns.

Authors:  Salih Ozgocmen; Huseyin Ozyurt; Sadik Sogut; Omer Akyol; Ozge Ardicoglu; Hulya Yildizhan
Journal:  Rheumatol Int       Date:  2005-11-10       Impact factor: 2.631

6.  The effect of anti-TNF agent on oxidation status in patients with ankylosing spondylitis.

Authors:  Murat Karkucak; Erhan Capkin; Ahmet Alver; Ayse Akyuz; Abdulkadir Kiris; Emel Ak; Murat Topbas; Mehmet Tosun
Journal:  Clin Rheumatol       Date:  2009-12-11       Impact factor: 2.980

7.  Evaluation of serum paraoxonase and arylesterase activities in ankylosing spondylitis patients.

Authors:  Fazile Hatipoglu Erdem; Saliha Karatay; Kadir Yildirim; Ahmet Kiziltunc
Journal:  Clinics (Sao Paulo)       Date:  2010-02       Impact factor: 2.365

8.  Thiol/disulfide homeostasis in patients with ankylosing spondylitis.

Authors:  Atalay Dogru; Ayse Balkarli; Gozde Yildirim Cetin; Salim Neselioglu; Ozcan Erel; Sevket Ercan Tunc; Mehmet Sahin
Journal:  Bosn J Basic Med Sci       Date:  2016-05-16       Impact factor: 3.363

9.  Evaluation of auditory and cochlear functions in ankylosing spondylitis patients according to the site of involvement.

Authors:  Duran Karataş; İsmail Doğan; Adnan Ekinci; Abdurrahman Yetiş; Müge Özcan
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-09-09       Impact factor: 2.503

10.  Serum oxidative-antioxidative status in patients with ankylosing spondilitis.

Authors:  Mehmet Karakoc; Ozlem Altindag; Huseyin Keles; Neslihan Soran; Sahabettin Selek
Journal:  Rheumatol Int       Date:  2007-04-19       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.